Global Health Solutions Announces Expansion of New Drug Development Program to Include Non-Antibiotic Superficial Infection Treatment Candidate

Global Health Solutions Founder and CEO, Bradley Burnam, states: “Standard of care, topical treatments for skin-based infection have seen little to no innovation in the past half-century. Yet, over this same period of time, we have seen a dramatic rise in the number of antimicrobial resistant organisms and resulting disease states. Our non-antibiotic new drug candidate is gentle, powerful, and has shown no signs of resistance among even the most virulent pathogens. We look forward to working closely with FDA to bring this important product to fruition.” Chief Medical Officer, Dr. Neil Ghodadra states: “As a physician, the growing number of antibiotic resistant organisms is alarming and presents daunting clinical implications. Doctors need viable, alternative treatment options for acute and chronic superficial infections, especially those colonized by drug resistant microbes. This is an important product not just for physicians, but for patients who may become victims of pathogens for which we lack sufficient tools to address.”

Global Health Solutions, LLC, is a concept-to-approval research and development entity focused on novel, best in class products for infection control, skin, and wound care. The company’s proprietary technologies are used every day by world-leading healthcare institutions to care for a variety of skin and wound conditions. For more information, visit www.globalhealthrx.com.

Forward Looking Statements Disclaimer: The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.

Media Contact: Nikki Hunter, [email protected]